IA and KKCL are the Editors in Chief of the Journal of Medical Economics. IA is an equity holder of Matric 45, LLC. MH is the Editor in Chief of the Expert Review of Pharmacoeconomics and Outcome Research. He has received research grants through institution from Amgen, Pfizer, Radius Health and Angelini Pharma, consulting fee from UCB, lecture fees from Mylan Pharmaceuticals and IBSA (paid to institution) and served as grant advisor for Pfizer (paid to institution). LC is the Editor in Chief of Current Medical Research and Opinion. In addition, served as Editor in Chief of the International Journal of Clinical Practice, through end 2019 and is the current Topic Editor for Psychiatry for Clinical Therapeutics; he is a reviewer for UpToDate; royalties from Springer Healthcare; he serves as a consultant to AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Marvin, Merck, Mitsubishi-Tanabe Pharma, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona, Vanda, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research; speaker for AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies; owns stocks (small number of shares of common stock) in Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer purchased >10 years ago, and stock options in Reviva. GLC is the Editor in Chief of ClinicoEconomics and Outcomes Research Journal. He has received, in the last three years, research grant through institution from: Abbott, AbbVie, Alfasigma, Almirall, AstraZeneca, Beigene, Biogen, Boehringer Ingelheim, Corza, Diasorin, Ferring, Galapagos, Gedeon Richter, Gene Predicts, Gerot Lannach, Ipsen, LEO Pharma, Menarini, Merck, Norgine, Novo Nordisk, Pfizer, Roche, Sandoz, Sanofi, Servier, Sobi and Teva; lecture fees from: DocGenerici, Novartis, Pfizer, Sandoz and Teva. The authors report no other conflicts of interest in this work.